Evidence map›Paper›PMID 39212542›Full record

ArticleJournal of immunology (Baltimore, Md. : 1950)2024

CD9 and Aryl Hydrocarbon Receptor Are Markers of Human CD19+CD14+ Atypical B Cells and Are Dysregulated in Systemic Lupus Erythematous Disease.

Lance K Blevins, D M Isha Olive Khan, Robert B Crawford, Christine O'Neill, Anthony P Bach, Jiajun Zhou, Peer W Karmaus, Dennis C Ang, Rupak Thapa, Norbert E Kaminski

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of immunology (Baltimore, Md. : 1950), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Lance K BlevinsInstitute of Integrative Toxicology, Michigan State University, East Lansing, MI.ORCID 0000-0002-8911-8843
D M Isha Olive KhanInstitute of Integrative Toxicology, Michigan State University, East Lansing, MI.ORCID 0000-0002-8314-3634
Robert B CrawfordInstitute of Integrative Toxicology, Michigan State University, East Lansing, MI.
Christine O'NeillAtrium Health Wake Forest Baptist School of Medicine, Winston Salem, NC.
Anthony P BachInstitute of Integrative Toxicology, Michigan State University, East Lansing, MI.ORCID 0000-0002-7571-4257
Jiajun ZhouInstitute of Integrative Toxicology, Michigan State University, East Lansing, MI.ORCID 0009-0006-7149-2382
Peer W KarmausNational Institute of Environmental Health Sciences, Research Triangle Park, NC.
Dennis C AngAtrium Health Wake Forest Baptist School of Medicine, Winston Salem, NC.ORCID 0000-0003-4161-5688
Rupak ThapaAtrium Health Wake Forest Baptist School of Medicine, Winston Salem, NC.ORCID 0009-0001-5232-0300
Norbert E KaminskiInstitute of Integrative Toxicology, Michigan State University, East Lansing, MI.ORCID 0000-0002-2144-428X

Funding

VOLATILE ORGANIC CONTAMINANTS--QUANTIFYING THEIR MOVEMENT IN THE UNSATURATED ZONEP42ES004911 · NIEHS · MICHIGAN STATE UNIVERSITY · PI Jamie J Bernard · 1989 to 2026
$64.9M
HHS | NIH | National Institute of Environmental Health Sciences (NIEHS) P42ES004911NIEHS NIH HHS P42 ES004911
6 · The paper itself

Abstract

Aryl hydrocarbon receptor (AHR) is a ligand-activated transcription factor whose expression regulates immune cell differentiation. Single-cell transcriptomic profiling was used to ascertain the heterogeneity of AHR expression in human B cell subpopulations. We identified a unique population of B cells marked by expression of AHR, CD9, and myeloid genes such as CD14 and CXCL8. Results were confirmed directly in human PBMCs and purified B cells at the protein level. TLR9 signaling induced CD14, CD9, and IL-8 protein expression in CD19+ B cells. CD14-expressing CD9+ B cells also highly expressed AHR and atypical B cell markers such as CD11c and TBET. In patients with active lupus disease, CD14+ and CD9+ B cells are dysregulated, with loss of CD9+ B cells strongly predicting disease severity and demonstrating the relevance of CD9+ B cells in systemic lupus erythematosus and autoimmune disease.

Indexed as

Antigens, CD19B-LymphocytesLipopolysaccharide ReceptorsLupus Erythematosus, SystemicReceptors, Aryl HydrocarbonTetraspanin 29AdultBasic Helix-Loop-Helix ProteinsBiomarkersB-Lymphocyte SubsetsFemaleHumansInterleukin-8MaleToll-Like Receptor 9AHR protein, humanAntigens, CD19Basic Helix-Loop-Helix ProteinsBiomarkersCD14 protein, humanCD19 molecule, humanCD9 protein, humanInterleukin-8Lipopolysaccharide ReceptorsReceptors, Aryl HydrocarbonTetraspanin 29TLR9 protein, humanToll-Like Receptor 9

Identifiers

PMID39212542
PMCPMC11458359

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.